SAN DIEGO, April 30, 2026
Contineum Therapeutics, Inc. announced positive topline results from its Phase 1b clinical trial of PIPE-791, a novel, non-opioid therapy candidate targeting chronic pain conditions, including chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). The exploratory study successfully met its primary endpoint of safety and tolerability, while also demonstrating encouraging trends across multiple pain-related efficacy measures, reinforcing the drug’s potential as a differentiated treatment option in a market with significant unmet need.
Strong Safety Profile and Trial Design Validation
The randomized, double-blind, placebo-controlled crossover study enrolled 43 patients across COAP and CLBP cohorts, evaluating a once-daily 10 mg oral dose of PIPE-791 over two treatment periods. Importantly, the trial confirmed that PIPE-791 was well tolerated, with most treatment-emergent adverse events classified as mild to moderate, and no serious adverse events reported. The most commonly observed side effects included headache and fatigue, with no clinically meaningful cardiovascular concerns such as blood pressure changes or orthostatic events. This safety consistency aligns with previous studies and strengthens confidence in PIPE-791’s clinical profile as it advances toward later-stage development.
Encouraging Efficacy Signals Across Pain Metrics
While the study was not powered for definitive efficacy outcomes, exploratory data revealed consistent improvements in pain reduction metrics compared to placebo. Using the Pain-Intensity Numerical Rating Scale (PI-NRS), patients treated with PIPE-791 demonstrated greater reductions in both average daily pain and worst daily pain scores. Notably, a higher proportion of patients achieved a clinically meaningful ≥30% reduction in pain from baseline, a key benchmark in chronic pain studies. Additional patient-reported outcomes, including improvements in functional measures such as the Modified Knee Injury and Osteoarthritis Outcome Scale (KOOS), further supported the drug’s potential therapeutic benefit. These findings suggest that PIPE-791 may offer clinically relevant pain relief without reliance on opioids, a major advantage in today’s treatment landscape.
Advertisement
Novel Mechanism Targets Root Cause of Chronic Pain
PIPE-791 is a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor, a target increasingly recognized for its role in neuropathic pain and central nervous system dysfunction. LPA1 activation contributes to nerve damage, increased neuronal excitability, and chronic inflammation, all of which drive persistent pain conditions. By inhibiting this pathway, PIPE-791 aims to address the underlying biological mechanisms of pain rather than merely masking symptoms, positioning it as a potentially transformative therapy. This mechanism also aligns with Contineum’s broader strategy of developing targeted, disease-modifying treatments in neuroscience and immunology.
Strategic Implications for Non-Opioid Pain Market
Chronic pain remains one of the most significant global healthcare challenges, with millions of patients seeking effective alternatives to opioids due to concerns around addiction, tolerance, and safety risks. The early clinical signals from PIPE-791 highlight its potential to become a next-generation non-opioid therapy, particularly for conditions like osteoarthritis and chronic back pain where treatment options are limited. The company indicated that these results will inform next-step clinical development plans, potentially advancing PIPE-791 into larger, more definitive trials to validate efficacy and support regulatory pathways.
Path Forward and Broader Pipeline Impact
Beyond chronic pain, PIPE-791 is also being explored in idiopathic pulmonary fibrosis (IPF), reflecting its broader applicability in diseases driven by inflammation and fibrosis. The successful demonstration of safety and early efficacy signals in this Phase 1b study provides a critical foundation for pipeline expansion and value creation, positioning Contineum Therapeutics as a key player in innovative small molecule drug development for complex diseases.
Overall, these findings mark an important milestone, demonstrating that PIPE-791 combines a strong safety profile with promising early efficacy, supporting its advancement as a potential best-in-class therapy in the rapidly evolving non-opioid pain treatment landscape.
Source: Contineum Therapeutics press release
